Compare AU
Compare SPY vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the SPDR S&P 500 ETF Trust (SPY) and the BetaShares Global Healthcare ETF - Currency Hedged (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
SPY | DRUG | |
---|---|---|
Popularity | Low | Low |
Pearlers invested | 209 | 63 |
Median incremental investment | $1,188.75 | $990.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,829.72 | $1,910.37 |
Average age group | 26 - 35 | 26 - 35 |
Key Summary
SPY | DRUG | |
---|---|---|
Strategy | SPY.AX was created on 2014-10-13 by SPDR. The fund's investment portfolio concentrates primarily on large cap equity. The Trust seeks to provide investment results that, before expenses, correspond generally to the price and yield performance of the S&P 500 Index (the Index). | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | Apple Inc (7.14 %) Microsoft Corp (6.56 %) NVIDIA Corp (6.16 %) | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) |
Top 3 industries | Information Technology (61.49 %) Consumer Discretionary (16.26 %) Communication Services (12.67 %) | Other (75.53 %) Communication Services (33.53 %) Health Care (24.47 %) |
Top 3 countries | United States (99.40 %) Switzerland (0.28 %) Netherlands (0.12 %) | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) |
Management fee | 0.0945 % | 0.57 % |
Key Summary
SPY | DRUG | |
---|---|---|
Issuer | SPDR | BetaShares |
Tracking index | S&P 500 | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.0945 % | 0.57 % |
Price | $943.24 | $8.27 |
Size | $958.570 billion | $182.401 million |
10Y return | 277.05 % | N/A |
Annual distribution yield (5Y) | 1.31 % | 1.90 % |
Market | ASX | ASX |
First listed date | 13/10/2014 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
SPY | DRUG | |
---|---|---|
Popularity | Low | Low |
Pearlers invested | 209 | 63 |
Median incremental investment | $1,188.75 | $990.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,829.72 | $1,910.37 |
Average age group | 26 - 35 | 26 - 35 |
Pros and Cons
SPY | DRUG | |
---|---|---|
Pros |
|
|
Cons |
|
|
SPY | DRUG |
---|---|
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |